B-ALL Data Reinforce Push for Risk-Tailored Care

A sizable share of patients with B-cell acute lymphoblastic leukemia (B-ALL) are not well served by one-size-fits-all treatment, and better tools are needed to identify who they are before, not after, they relapse, according to research presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden.^1,2

These 2 studies approached the question from opposite ends, with 1 testing a salvage therapy for patients who had already exhausted standard options¹ and the other mining a multinational database to sharpen genetic risk prediction.² Still, they arrived at a similar takeaway: outcomes in B-ALL increasingly hinge on how precisely a patient’s disease is characterized and how quickly that characterization is acted on.

How Does Donor-Derived CAR T-Cell Therapy Perform After Relapse?

The first study, from investigators at Beijing GoBroad Boren Hospital and the First Hospital of Jilin University, examined individuals with relapsed B-ALL after a second allogeneic hematopoietic stem cell transplantation, a group of patients for whom few options remain.¹ The 10 patients studied had a median age of 33 years (range, 5-58) and had already received a median of 4 prior treatment lines, with 7 having prior exposure to chimeric antigen receptor (CAR) T-cell therapy. Using donor-derived CD19- or CD22-directed CAR T-cells selected by antigen expression at relapse, all 10 patients achieved complete remission, including 8 (80%) with negative minimal residual disease.

With a median follow-up of 24.3 months, median disease-free survival was just 2.9 months, and median overall survival reached 10.9 months. The 12-month rates were 18.8% and 43.8%, respectively. Toxicity was manageable: cytokine release syndrome occurred in all patients but was predominantly low grade, with no treatment-related deaths. The authors concluded that donor-derived CAR T-cell therapy is a feasible bridge for this heavily pretreated population, even if it functions more as a salvage measure than a cure.

How Does Age Reshape B-ALL’s Genetic Risk Picture?

The second study used a broader lens.² Researchers working with the HARMONY Alliance Foundation, led by investigators at Newcastle University, analyzed copy number alterations (CNAs) in 3062 patients with B-ALL to test how age and cytogenetic risk group modify the prognostic weight of 8 specific genetic lesions: EBF1, IKZF1, CDKN2A/B, PAX5, ETV6, BTG1, RB1, and PAR1. Patients were sorted into 6 CNA profiles:

• No deletion (n = 1166)
• Isolated minor deletion (n = 356): BTG1, ETV6, or PAX5
• ETV6-plus (n = 135): ETV6 deletion plus 1 additional deletion (BTG1, CDKNA/B, or PAX5)
• IKZF1-plus: IKZF1 deletion together with at least 1 additional deletion (CDKNA/B, PAX, or PAR1); ERG deletion status was normal (n = 55) or unknown (n = 215)
• IKZF1-other: IKZ1 deletions not included in IKZF1-plus group (n = 287)
• All other deletion combinations (n = 848)

The combined frequency of favorable CNA profiles (no deletion, isolated minor deletion, or ETV6-plus) was 62% in children aged 1 to 9 years but only 33% in adults aged 20 to 83 years, whereas the frequency of IKZF1-related deletions rose steadily with age. Patients who fit the IKZF1-plus profile carried the worst prognosis across every age group, but the effect of the IKZF1-other deletions proved age-dependent.

Among patients with intermediate cytogenetic risk, the HR for the IKZF1-plus profile vs the IKZF1-other profile was 2.20 (95% CI, 1.43-3.44; P < .001) in patients younger than 18 years, compared with a nonsignificant 1.18 (95% CI, 0.73-1.89; P = .5) in adults. The authors concluded that both the frequency and the prognostic effect of CNA groups are tied to age and genetic background, arguing for age-aware rather than one-size-fits-all risk models.

How Do These Studies Intersect and What Are the Implications?

The Beijing GoBroad analysis shows what happens when a patient with high-risk biology is identified late,¹ and the HARMONY analysis aimed to catch high-risk biology early, before the point of a second transplant relapse.² Their findings converge on age as a variable that cannot be treated as an afterthought: the CAR T data spanned pediatric and adult patients alike,¹ and the HARMONY data suggest that a genetic lesion’s meaning can shift substantially between a child and an adult patient.²

These data also reflect recent research. A phase 2 “sandwich” CAR T-cell therapy/autologous transplant strategy found comparable survival across standard- and high-risk genetic subgroups,³ while data on obecabtagene autoleucel and brexucabtagene autoleucel show comparable results across age groups and abilities to predict relapse-free survival, respectively.⁴

Neither poster offers a finished solution, however. The Beijing GoBroad cohort was too small to draw firm conclusions about which patients benefit most from a second donor-derived CAR T-cell therapy product,¹ and the HARMONY authors caution that CNA groups explain only part of the variation in outcome.² But together, they reinforce that matching the intensity and type of therapy to a patient’s specific genetic and treatment-history profile, rather than to their diagnosis alone, is likely to be the next lever for improving outcomes in relapsed and high-risk B-ALL.^1,2

References

1. Li B, Lin Y, Li W, et al. Donor-derived CAR-T therapy for relapse of B-ALL after second allogeneic hematopoietic stem cell transplantation. Presented at: EHA 2026 Congress; June 11-14, 2026; Stockholm, Sweden. Poster PS1499.
2. Moorman A, Lawal S, Gibson J, et al. Influence of age and cytogenetic risk group on the prognostic effect of key copy number alterations in B-ALL. Presented at: EHA 2026 Congress; June 11-14, 2026; Stockholm, Sweden. Poster PS1467.
3. DiEugenio J. Sequential CAR T-cell therapy and ASCT yields durable remissions in Ph-negative B-ALL. OncLive^®. November 12, 2025. Accessed July 30, 2026. https://www.onclive.com/view/sequential-car-t-cell-therapy-and-asct-yields-durable-remissions-in-ph-negative-b-all
4. Mattina C. Obe-cel outcomes by age; brexu-cel expansion as a predictor of relapse-free survival in R/R ALL. AJMC^®. July 30, 2025. Accessed July 30, 2026. https://www.ajmc.com/view/obe-cel-outcomes-by-age-brexu-cel-expansion-as-a-predictor-of-relapse-free-survival-in-r-r-all